Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)±-5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy.

被引：0
作者：
Macarulla, Teresa Mercade
Hubner, Richard
Blanc, Jean-Frederic
Wang-Gillam, Andrea
Li, Chung-Pin
Bodoky, Gyorgy
Dean, Andrew Peter
Yanshen, Shan
Jameson, Gayle S.
Lee, Kyung-Hun
Chiu, Chang-Fang
Schwartsmann, Gilberto
Braiteh, Fadi S.
Cunningham, David
Chen, Li-Tzong
Von Hoff, Daniel D.
Mamlouk, Khalid Kevin
de Jong, Floris A.
Siveke, Jens T.
机构：
[1] Vall d Hebron Univ Hosp, Inst Oncol, Barcelona, Spain
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] CHU Bordeaux, Pole ADEN, Hop Haut Leveque, Bordeaux, France
[4] Washington Univ, Sch Med St Louis, St Louis, MO USA
[5] Taipei Vet Gen Hosp, Taipei, Taiwan
[6] Szent Laszlo Teaching Hosp, Budapest, Hungary
[7] St John God Hosp, Subiaco, WA, Australia
[8] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[9] Honor Hlth, Virginia G Piper Canc Ctr, Scottsdale, AZ USA
[10] Seoul Natl Univ Hosp, Seoul, South Korea
[11] China Med Univ First Hosp, Taichung, Taiwan
[12] Fed Univ, Porto Alegre, RS, Brazil
[13] Comprehens Canc Centers Nevada, Las Vegas, NV USA
[14] Royal Marsden NHS Fdn Trust, London, England
[15] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan
[16] Ipsen Biosci Inc, Cambridge, MA USA
[17] Shire GmbH, Zug, Switzerland
[18] Univ Hosp Essen, West German Canc Ctr, Essen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.410
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
410
引用
收藏
页数：1
相关论文
共 49 条
[41]   Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1 [J].
Hubner, R. ;
Cubillo, A. ;
Blanc, J-F. ;
Melisi, D. ;
von Hoff, D. D. ;
Wang-Gillam, A. ;
Chen, L-T. ;
Becker, C. ;
Mamlouk, K. ;
Belanger, B. ;
Yang, Y. ;
de Jong, F. ;
Siveke, J. T. .
ANNALS OF ONCOLOGY, 2016, 27
[42]   Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY). [J].
Yoo, Changhoon ;
Kim, Kyu-Pyo ;
Kim, Ilhwan ;
Kang, Myoung Joo ;
Cheon, Jaekyung ;
Kang, Byung Woog ;
Ryu, Hyewon ;
Jeong, Jae Ho ;
Lee, Ji Sung ;
Kim, Kyung Won ;
Ryoo, Baek-Yeol .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[43]   Multicenter randomized phase II trial of 5-fluorouracil/leucovorin (5-FU/LV) with or without liposomal irinotecan (nal-IRI) in metastatic biliary tract cancer (BTC) as second-line therapy after progression on gemcitabine plus cisplatin (GemCis): NIFTY trial [J].
Yoo, C. ;
Jeong, J. H. ;
Kim, K-P. ;
Cheon, J. ;
Kim, I. ;
Kang, M. ;
Ryu, H. ;
Kang, B. W. ;
Ryoo, B-Y. .
ANNALS OF ONCOLOGY, 2019, 30
[44]   First-line (1L) liposomal irinotecan+5 fluorouracil/leucovorin (5-FU/LV) + oxaliplatin (OX) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC): Exploratory subgroup analyses of survival by changes in CA 19-9 levels [J].
Dean, A. ;
Bekaii-Saab, T. ;
Boland, P. M. ;
Dayyani, F. ;
Macarulla, T. ;
Mody, K. ;
Belanger, B. ;
Maxwell, F. ;
Moore, Y. ;
Wang, T. ;
Zhang, B. ;
Wainberg, Z. A. .
ANNALS OF ONCOLOGY, 2020, 31 :S941-S942
[45]   Phase 1b study of vactosertib in combination with nal-IRI plus 5FU/LV in patients with metastatic pancreatic ductal adenocarcinoma who have failed first-line gemcitabine/nab-paclitaxel [J].
Park, Joon Oh ;
Kim, Seung Tae ;
Hong, Jung Yong ;
Kim, Seong-Jin ;
Park, Young Suk .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[46]   NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). [J].
Wainberg, Zev A. ;
Melisi, Davide ;
Macarulla, Teresa ;
Pazo-Cid, Roberto ;
Chandana, Sreenivasa R. ;
De La Fouchardiere, Christelle ;
Dean, Andrew Peter ;
Kiss, Igor ;
Lee, Woojin ;
Goetze, Thorsten Oliver ;
Van Cutsem, Eric ;
Paulson, Andrew Scott ;
Bekaii-Saab, Tanios S. ;
Pant, Shubham ;
Hubner, Richard ;
Xiao, Zhimin ;
Chen, Huanyu ;
Benzaghou, Fawzi ;
O'Reilly, Eileen Mary .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 :LBA661-LBA661
[47]   NAPOLI-3: A randomized, open-label Phase 3 study of liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) [J].
Goetze, T. ;
Melisi, D. ;
Macarulla, T. ;
Pazo Cid, A. R. ;
Chandana, R. S. ;
De La Fouchardiere, C. ;
Dean, A. ;
Kiss, I. ;
Lee, Jin W. ;
Van Cutsem, E. ;
Paulson, S. ;
Bekaii-Saab, T. ;
Pant, S. ;
Hubner, R. ;
Xiao, Z. ;
Chen, H. ;
Benzaghou, F. ;
O'Reilly, E. ;
Wainberg, A. Z. .
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 :12-14
[48]   NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma [J].
Dean, Andrew ;
Wainberg, Zev A. ;
Bekaii-Saab, Tanios S. ;
Hubner, Richard ;
Macarulla, Teresa ;
Paulson, Andrew Scott ;
Cutsem, Eric V. ;
Maxwell, Fiona ;
Moore, Yan ;
Wang, Haofei Tiffany ;
Zhang, Bin ;
O'Reilly, Eileen .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 :202-203
[49]   NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. [J].
Wainberg, Zev A. ;
Bekaii-Saab, Tanios S. ;
Hubner, Richard ;
Macarulla, Teresa ;
Paulson, Andrew Scott ;
Van Cutsem, Eric ;
Maxwell, Fiona ;
Moore, Yan ;
Wang, Haofei Tiffany ;
Zhang, Bin ;
O'Reilly, Eileen Mary .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345